Rhumbline Advisers bought a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 19,008 shares of the company's stock, valued at approximately $331,000.
Several other hedge funds have also made changes to their positions in BCAX. RA Capital Management L.P. acquired a new position in Bicara Therapeutics in the third quarter valued at approximately $177,169,000. FMR LLC acquired a new position in shares of Bicara Therapeutics in the 3rd quarter valued at $57,913,000. Braidwell LP purchased a new position in shares of Bicara Therapeutics during the 3rd quarter worth $42,219,000. Janus Henderson Group PLC acquired a new stake in shares of Bicara Therapeutics during the 3rd quarter worth about $30,329,000. Finally, Baker BROS. Advisors LP purchased a new stake in Bicara Therapeutics in the 3rd quarter valued at about $21,225,000.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on BCAX shares. Wedbush reiterated an "outperform" rating and set a $31.00 price target on shares of Bicara Therapeutics in a research report on Wednesday, February 12th. HC Wainwright lifted their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a "buy" rating in a report on Monday, January 27th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Bicara Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $41.20.
Get Our Latest Stock Report on BCAX
Bicara Therapeutics Stock Up 5.1 %
Shares of BCAX stock opened at $16.55 on Monday. Bicara Therapeutics Inc. has a fifty-two week low of $11.10 and a fifty-two week high of $28.09. The company has a 50 day simple moving average of $13.53.
Bicara Therapeutics Company Profile
(
Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
See Also
Want to see what other hedge funds are holding BCAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
